Synthesis and optimization of fluoxetine-loaded polymeric nanoparticles for dual therapeutic applications in cancer and depression
DARU Journal of Pharmaceutical Sciences · 2025
DOI: 10.1007/s40199-025-00561-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, 2025. Verfasst von Muhammad Shoaib und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy & Pharmaceutical Sciences, Research Institute of Pharmaceutical Sciences, University of K…. Hauptthemen laut MEDLINE: Fluoxetine, Nanoparticles, Depression, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Higher Education Commision, Pakistan.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Fluoxetine, an antidepressant, has shown potential anticancer effects. However, its therapeutic efficacy is limited by its poor bioavailability and rapid metabolism. Nanotechnology is advancing medicine, particularly in developing suitable drug delivery systems to improve therapeutic effects and reduce drug side effects. OBJECTIVES: This study aims to synthesize chemically conjugated fluoxetine-dextran nanoparticles (FLX-DEX NPs) to improve the pharmacokinetic profile in plasma and brain to improve antidepressant and anticancer activity against glioma and breast cancer. Besides this, it also targets to reduce the side effects of the drug via delivering the payload to pathological cells. METHODS: Fluoxetine was conjugated to aldehyde-functionalized dextran to give pH stimulus release from its nanoparticles. The spectral and morphological characterization was performed using dynamic light scattering (DLS), atomic force microscopy (AFM), UV, FTIR and 1HNMR. The stability was determined using thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) to evaluate thermal stability and phase transitions of the fluoxetine-dextran nanoparticles. Non-compartmental model was employed to compare the pharmacokinetics of FLX and its nanoparticles in the plasma and various parts of Sprague-Dawley rats. Furthermore, the in vitro safety profile, cytotoxic activity on MCF-7 breast cancer and U87 glioma cell lines and antidepressant effects were measured using various animal models. The levels of dopamine and serotonin in brain were monitored after a fortnight treatment of FLX and its NPs. RESULTS: The nanoparticles were found to be round to slightly elliptical, having size less than 50 nm and charge -15-20 mV. These nanoparticles were more stable to the drug as depicted by thermoanalysis. The particles showed a controlled and pH stimuli released. The Cmax, Tmax, t1/2, volume of distribution and plasma elimination values were 5.23, 2, 15 h, 1.94 and 0.045, respectively, on oral administration of 30 mg/ kg/day. They passed 20% and 18% viability against MCF-7 and glioma cancer at 10 mg/kg/day dose without retarding its anti-depressant effect. CONCLUSION: FLX-DEX NPs offer dual therapeutic benefits, enhancing anticancer activity and antidepressant effects. The extended half-life and controlled fluoxetine release improved the pharmacokinetics and therapeutic outcomes, suggesting a promising nanotechnology-based approach for cancer and depression treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy & Pharmaceutical Sciences, Research Institute of Pharmaceutical Sciences, University of Karachi, Karachi, 75270, Pakistan.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy & Pharmaceutical Sciences, Research Institute of Pharmaceutical Sciences, University of Karachi, Karachi, 75270, Pakistan. asia.naz@uok.edu.pk.
- Dow College of Pharmacy. Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi, Pakistan.
- International Centre for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Förderung
- Higher Education Commision, Pakistan
Zitieren
APA
Shoaib, M., Arif, H., Awan, A. N., Khan, M. M., Batool, S., & Ahmed, S. (2025). Synthesis and optimization of fluoxetine-loaded polymeric nanoparticles for dual therapeutic applications in cancer and depression. DARU Journal of Pharmaceutical Sciences. https://doi.org/10.1007/s40199-025-00561-2
Vancouver
Shoaib M, Arif H, Awan AN, Khan MM, Batool S, Ahmed S. Synthesis and optimization of fluoxetine-loaded polymeric nanoparticles for dual therapeutic applications in cancer and depression. DARU Journal of Pharmaceutical Sciences. 2025. doi:10.1007/s40199-025-00561-2
BibTeX
@article{Shoaib2025,
author = {Shoaib, Muhammad and Arif, Hira and Awan, Asia Naz and Khan, Moona Mehboob and Batool, Sehrish and Ahmed, Shakil},
title = {Synthesis and optimization of fluoxetine-loaded polymeric nanoparticles for dual therapeutic applications in cancer and depression},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2025},
doi = {10.1007/s40199-025-00561-2}
}
EUVIMED